Summary of adverse events reported for visit 2 (2-3 days after initial vaccination) and visit 3 (14 days after initial vaccination)
| . | Visit 2 . | n . | Visit 3 . | n . |
|---|---|---|---|---|
| Arthralgia | 2 (5%) | 41 | 3 (7%) | 41 |
| Myalgia | 9 (22%) | 41 | 4 (10%) | 41 |
| Nausea | 1 (2%) | 41 | 1 (2%) | 41 |
| Vomiting | 0 | 41 | 2 (5%) | 41 |
| Vaccine site redness | 3 (7%) | 41 | 0 | 41 |
| Vaccine site pain | 11 | 41 | 5 (12%) | 41 |
| Vaso-occlusive pain | 3 (7%) | 41 | 5 (12%) | 41 |
| Additional pain meds taken | 3 (100%) | 3 | 3 (60%) | 5 |
| Seen in clinic or ER for pain | 2 (67%) | 3 | 0 | 5 |
| Admitted for pain | 0 | 3 | 1 (20%) | 5 |
| Fever | 2 (5%) | 41 | 2 (5%) | 41 |
| Chills | 1 (2%) | 41 | 3 (7%) | 41 |
| Headache | 3 (7%) | 41 | 2 (5%) | 41 |
| . | Visit 2 . | n . | Visit 3 . | n . |
|---|---|---|---|---|
| Arthralgia | 2 (5%) | 41 | 3 (7%) | 41 |
| Myalgia | 9 (22%) | 41 | 4 (10%) | 41 |
| Nausea | 1 (2%) | 41 | 1 (2%) | 41 |
| Vomiting | 0 | 41 | 2 (5%) | 41 |
| Vaccine site redness | 3 (7%) | 41 | 0 | 41 |
| Vaccine site pain | 11 | 41 | 5 (12%) | 41 |
| Vaso-occlusive pain | 3 (7%) | 41 | 5 (12%) | 41 |
| Additional pain meds taken | 3 (100%) | 3 | 3 (60%) | 5 |
| Seen in clinic or ER for pain | 2 (67%) | 3 | 0 | 5 |
| Admitted for pain | 0 | 3 | 1 (20%) | 5 |
| Fever | 2 (5%) | 41 | 2 (5%) | 41 |
| Chills | 1 (2%) | 41 | 3 (7%) | 41 |
| Headache | 3 (7%) | 41 | 2 (5%) | 41 |
This reflects responses after contact by phone, email, or text.
ER, emergency room.